Gland Pharma Limited (NSE: GLAND)

Market Cap	314.02B
Revenue (ttm)	58.58B
Net Income (ttm)	7.22B
Shares Out	164.75M
EPS (ttm)	43.84
PE Ratio	43.48
Forward PE	32.51
Dividend	20.00 (1.05%)
Ex-Dividend Date	Aug 16, 2024

Volume	144,100
Open	1,882.00
Previous Close	1,891.80
Day's Range	1,879.50 - 1,916.95
52-Week Range	1,475.05 - 2,220.95
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 4, 2024

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 4,217
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GLAND

Financial Performance

In 2023, Gland Pharma's revenue was 56.65 billion, an increase of 56.29% compared to the previous year's 36.25 billion. Earnings were 7.72 billion, a decrease of -1.10%.